Team:British Columbia

UBC iGEM 2021

iGEM 2021 Giant Jamboree Best Diagnostics Nominee and Gold Medal Recipient!

What if we could personalize cancer treatment through synthetic biology?

Our Solution

We want to create a bacterial platform that can report on tumour immune status in-vivo, and generate a reporter that can be easily retrieved in urine.

solution pipeline

[1] Vogenberg FR, Barash CI, Pursel M. (2010). Personalized Medicine. P&T, 35(10), 560-576.

[2] Sharma, P. et al. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 168(4), 707–723.

[3] Bonaventura, P. et al. (2019). Cold tumors: A therapeutic challenge for immunotherapy. Frontiers in Immunology, 10.

[4] Ilié, M., & Hofman, P. (2016). Pros: Can tissue biopsy be replaced by liquid biopsy?. Translational lung cancer research, 5(4), 420–423.

[5] Trebeschi, S. et al. (2019). Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Annals of Oncology 30(6): 998-1004.

[6] Galli, F. et al. (2020). Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. Journal of Experimental & Clinical Cancer Research, 39(1).

[7] Pilard, C. et al. (2021). Cancer immunotherapy: It’s time to better predict patients’ response. British Journal of Cancer.